News Search Results
Nov 25, 2025, 20:16 ET Prestige Biopharma and Biosidus Enter Exclusive License Agreement for Tuznue® Commercialization in Latin America
Biopharma, a biopharmaceutical company specializing in antibody therapeutics, today announced an exclusive license and supply agreement with Biosidus, a biotechnology company headquartered in Buenos Aires, Argentina, with decades of experience in biosimilar development and commercialization, for the commercialization
More news about: Prestige Biopharma Limited
Nov 25, 2025, 16:31 ET MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman
FRANCISCO, Nov. 25, 2025 /PRNewswire/ -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities fraud class action lawsuit after its share price plummeted nearly 90% in a single day. The
More news about: Hagens Berman Sobol Shapiro LLP
Nov 25, 2025, 11:00 ET Exyte completes Pharmaplan integration: A-to-Z execution in GMP facilities
Exyte announced the acquisition of Pharmaplan to establish a European champion and deepen partnerships with Europe's fast-growing biotechnology and pharmaceutical sectors. Pharmaplan contributes a pan-European footprint of locations and specialist teams now operating within
More news about: Exyte
Nov 25, 2025, 10:16 ET Biosurfactants Market worth $2.89 billion by 2030 - Exclusive Report by MarketsandMarkets™
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=163644922Key Players The key players profiled in the report include Evonik Industries AG (Germany), Shaanxi Deguan Biotechnology Co., Ltd (China), Biotensidon GmbH (Germany), Saraya Co., Ltd. (Japan), Allied Carbon Solutions Co., Ltd. (Japan), Daqing VICTEX Chemical Industries
More news about: MarketsandMarkets
Nov 25, 2025, 10:06 ET Innova Therapeutics to Advance Novel Cancer Treatment with Enci Therapeutics Acquisition
non-canonical Wnt/Ca2+ signaling pathway.About Innova Therapeutics, Inc.Innova Therapeutics is a Charleston, South Carolina based biotechnology company developing a monoclonal antibody (mAb) platform targeting a protein that is highly expressed in various solid cancers and shown to correlate
More news about: Innova Therapeutics
Nov 25, 2025, 10:06 ET Innova Therapeutics to Advance Novel Cancer Treatment with Enci Therapeutics Acquisition
non-canonical Wnt/Ca2+ signaling pathway.About Innova Therapeutics, Inc.Innova Therapeutics is a Charleston, South Carolina based biotechnology company developing a monoclonal antibody (mAb) platform targeting a protein that is highly expressed in various solid cancers and shown to correlate
More news about: Innova Therapeutics
Nov 25, 2025, 09:00 ET Lexogen Successfully Completes Large-Scale Human Primary Cell Next Gen Sequencing Project with Ochre Bio
Ochre Bio is a biotechnology company developing RNA medicines for under-treated chronic liver diseases. Ochre builds and integrates extensive human liver data, including proprietary
More news about: LEXOGEN
Nov 25, 2025, 09:00 ET Lexogen Successfully Completes Large-Scale Human Primary Cell Next Gen Sequencing Project with Ochre Bio
Ochre Bio is a biotechnology company developing RNA medicines for under-treated chronic liver diseases. Ochre builds and integrates extensive human liver data, including proprietary
More news about: LEXOGEN
Nov 25, 2025, 08:30 ET Halozyme to Participate in the 8th Annual Evercore Healthcare Conference
than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen
More news about: Halozyme Therapeutics, Inc.
Nov 25, 2025, 08:30 ET Mastering Inspection Readiness for FDA's AI Tool Elsa, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Nov 25, 2025, 08:30 ET Overcoming Pharmaceutical Supply Chain Risks with AI Tools, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Nov 25, 2025, 07:45 ET Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models
publication in Vaccines, a successful pre-IND meeting with the U.S. Food and Drug Administration (FDA), and growing third-party recognition from the biotechnology and scientific communities. Lunai has proposed a Phase I clinical trial evaluating its Dendritic Cell Combination Therapy (DCCT) across several
More news about: Lunai Bioworks Inc.
Nov 25, 2025, 07:30 ET Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
LinkedIn.5. About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities.
More news about: Eisai Inc.
Nov 25, 2025, 07:05 ET REGENXBIO to Participate in Upcoming Investor Conference
replay of the webcast will be available for approximately 30 days following the event.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Nov 25, 2025, 05:01 ET Generic Drugs Market Size to Worth USD 898 Billion by 2035, at a CAGR of 5.75% | Research by Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Nov 25, 2025, 05:00 ET Exyte completes Pharmaplan integration: A-to-Z execution in GMP facilities
September 2024, Exyte announced the acquisition of Pharmaplan to establish a European champion and deepen partnerships with Europe's fast-growing biotechnology and pharmaceutical sectors. Pharmaplan contributes a pan-European footprint of locations and specialist teams now operating within Exyte's Biopharma
More news about: Exyte
Nov 24, 2025, 19:42 ET Phrontline Biopharma Raises $60 Million in Pre-A+ Financing to Advance Global Development of Bispecific and Dual-Payload ADCs
strategic partnerships. Building a Leading Bispecific and Dual-Payload ADC PlatformFounded in 2022, Phrontline is among the first biotechnology companies globally to focus on bispecific antibody ADCs (BsAb-ADCs) and dual-payload ADCs. The company has built an end-to-end ADC
More news about: Phrontline Biopharma
Nov 24, 2025, 16:30 ET Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Nov 24, 2025, 16:10 ET AMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Nov 24, 2025, 16:01 ET Innocan Pharma Announces Promising Translational Evidence from a Pain Relief Study of Repeated LPT-CBD Administration in Goats
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled "Liposomal-synthetic-cannabidiol: preliminary translational evidence
More news about: Innocan Pharma Corporation
Nov 24, 2025, 16:01 ET Innocan Pharma Announces Promising Translational Evidence from a Pain Relief Study of Repeated LPT-CBD Administration in Goats
2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled "Liposomal-synthetic-cannabidiol: preliminary translational evidence
More news about: Innocan Pharma Corporation
Nov 24, 2025, 16:00 ET AMGEN TO PRESENT AT THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Nov 24, 2025, 12:00 ET Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Nov 24, 2025, 11:58 ET Enquyst Technologies Demonstrates First-in-Class, Chromatography-free Downstream Processing of a Monoclonal Antibody (mAb) with its Patented Isoelectric Point Purification (IPP) Technology Platform and Announces Receipt of a National Institute for Innovation in Manufacturing Biopharmaceutical (NIIMBL) Led Gates Grand Challenge Program Award
systems to its collaboration partners and customers starting in 2026.About Enquyst TechnologiesEnquyst Technologies is a private biotechnology company that is disrupting the way that biological drugs are manufactured. Enquyst's mission is to develop next-generation biomanufacturing and
More news about: Enquyst Technologies
Nov 24, 2025, 11:39 ET Aesthetic Fillers Market Surges to USD 8.45 Billion by 2033, Propelled by 7.2% CAGR - Verified Market Reports®
Type (Liquid Chromatography (LC) Gas Chromatography (GC)), By Application (Pharmaceuticals, Food & Beverage Testing), By End-User Industry (Biotechnology, Chemical Manufacturing), By Technology (Manual Chromatography Systems, Automated Chromatography Systems), By Component (Instruments (detectors,
More news about: Verified Market Reports